Axsome Therapeutics, Inc. (LON:0HKF)
Market Cap | 4.03B |
Revenue (ttm) | 334.49M |
Net Income (ttm) | -215.38M |
Shares Out | n/a |
EPS (ttm) | -4.47 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 508 |
Average Volume | 402 |
Open | 102.97 |
Previous Close | 104.92 |
Day's Range | 102.97 - 104.19 |
52-Week Range | 73.05 - 141.00 |
Beta | n/a |
RSI | 64.77 |
Earnings Date | Aug 4, 2025 |
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]
Financial Performance
In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.
Financial numbers in USD Financial StatementsNews
Axsome Therapeutics Champions Brain Health During Alzheimer’s & Brain Awareness Month
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is ...

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is...

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...

Axsome initiated with an Outperform at Oppenheimer on revenue boost
Axsome Therapeutics (AXSM) is set for growth with Auvelity, initiated at Outperform. Read more here.

Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, ...

Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Axsome Therapeutics enters $570M term loan, credit facility with Blackstone

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervo...
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025
Axsome Therapeutics reports 62% YoY revenue growth in Q1 2025, fueled by Auvelity & Sunosi. Key milestones include Symbravo launch & AXS-14 FDA decision.
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ETCompany ParticipantsDarren Opland - Director, Corporate...

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Axsome Therapeutics Inc (NASDAQ: AXSM) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million. Auvelity (oral antid...

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Axsome Therapeutics Inc AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.
Axsome Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation
Axsome Therapeutics GAAP EPS of -$1.22 beats by $0.13, revenue of $121.5M beats by $2.22M

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY ® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI ® 1Q 20...
Earnings Scheduled For May 5, 2025
Companies Reporting Before The Bell • Recursion Pharmaceuticals (NASDAQ: RXRX) is likely to report quarterly loss at $0.52 per share on revenue of $18.08 million. • Freshpet (NASDAQ: FRPT) is estima...

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...

Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...

Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached the...

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ...

Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) bre...

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page ....